Related Experiment Video
Updated: Jan 12, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Novel AMP-activated protein kinase activators and their potential for mitigating renal injury and fibrosis
1Department of Nephrology (Kidney Laboratory), Austin Health, Melbourne, Victoria, Australia.
Abstract:
Disordered energy regulation within the kidney represents an important therapeutic target to reduce the severity of acute kidney injury and subsequent fibrosis. AMP-activated protein kinase (AMPK) is stimulated in situations of cellular energy deprivation to act as a key regulator of cellular and systemic energy metabolism. AMPK activation has been shown to be protective against renal injury and fibrosis in numerous experimental studies using metformin and aminoimidazole-4-carboxamide ribonucleotide. However, studies with these traditional AMPK activators are limited by these agents being indirect activators of AMPK, with unwanted off-target effects that may limit their use. Novel AMPK activators represent a promising new therapy in kidney protection, as well as in a range of other chronic diseases. AMPK phosphorylates multiple targets to regulate numerous pathways, thereby enabling multiple mechanisms to reduce kidney injury. This review outlines important mechanisms of renal injury and fibrosis as well as the current landscape of novel AMPK activators. It outlines experimental evidence for mechanisms of novel AMPK activators and how these relate to injury and fibrosis within the kidney. Finally, it discusses the potential of these agents, as well as current challenges in their development. SIGNIFICANCE STATEMENT: Multiple studies have identified dysregulated energy metabolism as a treatment target for kidney disease, revealing novel AMP-activated protein kinase (AMPK) activators as a promising new therapy to address this opportunity for protection against kidney injury and fibrosis. Despite this promise, novel AMPK activators are yet to find a clinical role for kidney disease or other conditions. Barriers to be considered in future studies include concerns about cardiac hypertrophy and oncogenesis as well as elucidation of precise pharmacokinetic properties. Nonetheless, the large volume of beneficial preclinical data for kidney health provides motivation for future studies to address these needs.
Insights
Novel AMP-activated protein kinase (AMPK) activators show promise for treating kidney disease by improving energy regulation. These new therapies offer potential protection against kidney injury and fibrosis, though clinical application faces challenges.
Area of Science:
- Biochemistry
- Nephrology
- Pharmacology
Background:
- Kidney injury and fibrosis are linked to disordered cellular energy metabolism.
- AMP-activated protein kinase (AMPK) regulates energy metabolism and is protective in kidney injury models.
- Traditional AMPK activators have limitations due to indirect action and off-target effects.
Purpose of the Study:
- To review mechanisms of kidney injury and fibrosis.
- To outline the current landscape of novel AMPK activators.
- To discuss experimental evidence and potential of novel AMPK activators in kidney protection.
Main Methods:
- Review of existing literature on kidney injury, fibrosis, and AMPK activators.
- Analysis of experimental data on novel AMPK activator mechanisms.
- Discussion of preclinical findings and clinical development challenges.
Main Results:
- Dysregulated energy metabolism is a key target for kidney disease treatment.
- Novel AMPK activators demonstrate protective mechanisms against kidney injury and fibrosis in preclinical studies.
- Existing evidence supports AMPK activators as a promising therapeutic strategy for kidney health.
Conclusions:
- Novel AMPK activators represent a promising therapeutic avenue for kidney injury and fibrosis.
- Further research is needed to address challenges such as cardiac hypertrophy, oncogenesis, and pharmacokinetics for clinical translation.
- Despite challenges, significant preclinical data motivates continued development of novel AMPK activators for kidney disease.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Antihypertensive Drugs: Direct Renin Inhibitors
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury I: Introduction

